Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) in Q4 CY2024, with sales flat year on year at $594 million. Its ...

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings tomorrow morning. Here’s what to look ...

Portfolio Cash Flow is calculated as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma’s business that can be redeployed into ...

Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...

Sabine Royalty Trust offers a high-yield, inflation-hedged investment with steady royalty income and minimal operational ...

Ceva reported a solid financial performance with revenue and adjusted EPS meeting or surpassing expectations.

Royalty Receipts grew 12% to $729 million in the fourth quarter and 13% to $2,771 million for full year 2024, driven by strong performance from ...

As a leader in community engagement, Sam has directed workshops to help organizations develop frameworks for trust and accountability while expanding business development in Indigenous sectors.